Ginger has credible evidence for several specific symptom targets, especially pregnancy-related and postoperative nausea, osteoarthritis pain, and menstrual pain. Blood-sugar and blood-pressure findings come mainly from higher-risk groups and may not transfer to healthy adults. Digestive irritation and medication interactions matter; direct longevity benefit lacks human outcome evidence. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Home blood pressure | Below 120/80 mmHg if tolerated; track change from baseline | Detect benefit or excessive lowering |
| Fasting glucose | 70–90 mg/dL; track change from baseline | Detect blood-sugar response |
| Glycated hemoglobin | 4.8%–5.4%; individualized diabetes target when applicable | Shows approximately three-month glucose exposure |
| International normalized ratio | No established functional target; track change relative to prescribed range, commonly 2.0–3.0 | Detect altered blood-clotting medication effect |
Cadence: Tolerability at 1 week; symptom or home marker at 4 weeks; decision point by 8–12 weeks; ongoing reassessment every 3–6 months. Laboratory cadence follows the underlying condition.